Vasopressin Patent Expiration
Vasopressin is Used for increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. It was first introduced by Ph Health Ltd
Vasopressin Patents
Given below is the list of patents protecting Vasopressin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vasostrict | US10010575 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US12186362 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9375478 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9687526 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9744209 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9744239 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9750785 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9919026 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9925233 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9925234 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9937223 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9962422 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9968649 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9974827 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
| Vasostrict | US9981006 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Vasopressin's patents.
Latest Legal Activities on Vasopressin's Patents
Given below is the list recent legal activities going on the following patents of Vasopressin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Nov, 2023 | US9375478 |
| Email Notification Critical
| 28 May, 2022 | US9925234 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 27 May, 2022 | US9925234 |
| Correspondence Address Change Critical
| 26 May, 2022 | US9925234 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Dec, 2021 | US10010575 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9968649 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9974827 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9981006 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9962422 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Sep, 2021 | US9937223 |
Vasopressin's Family Patents
